Dyne Therapeutics, Inc. (NASDAQ:DYN) COO Susanna Gatti High Sells 8,976 Shares

Dyne Therapeutics, Inc. (NASDAQ:DYN) COO Susanna Gatti High sold 8,976 shares of the company’s stock in a transaction that occurred on Wednesday, September 18th. The shares were sold at an average price of $34.41, for a total value of $308,864.16. Following the sale, the chief operating officer now directly owns 131,636 shares of the company’s stock, valued at $4,529,594.76. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Susanna Gatti High also recently made the following trade(s):

• On Friday, June 21st, Susanna Gatti High sold 29,787 shares of Dyne Therapeutics stock. The shares were sold at an average price of $35.01, for a total value of $1,042,842.87.
• On Monday, June 24th, Susanna Gatti High sold 10,163 shares of Dyne Therapeutics stock. The stock was sold at an average price of $35.33, for a total value of $359,058.79.

Dyne Therapeutics Stock Performance

DYN stock traded up $2.07 during midday trading on Thursday, hitting $36.41. 2,431,913 shares of the stock were exchanged, compared to its average volume of 1,597,111. The stock’s 50-day moving average price is $41.28 and its 200-day moving average price is $33.47. The stock has a market cap of $3.18 billion, a price-to-earnings ratio of -9.31 and a beta of 1.07. Dyne Therapeutics, Inc. has a fifty-two week low of $6.40 and a fifty-two week high of $47.45.

Dyne Therapeutics (NASDAQ:DYN) last announced its quarterly earnings results on Monday, August 12th. The company reported ($0.70) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.72) by $0.02. Research analysts anticipate that Dyne Therapeutics, Inc. will post -2.96 EPS for the current year.

Hedge Funds Weigh In On Dyne Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in DYN. Nisa Investment Advisors LLC grew its position in shares of Dyne Therapeutics by 904.1% in the second quarter. Nisa Investment Advisors LLC now owns 743 shares of the company’s stock valued at $26,000 after purchasing an additional 669 shares during the last quarter. Amalgamated Bank raised its position in shares of Dyne Therapeutics by 39.9% during the 2nd quarter. Amalgamated Bank now owns 2,792 shares of the company’s stock worth $99,000 after purchasing an additional 796 shares during the last quarter. Ameritas Investment Partners Inc. lifted its stake in Dyne Therapeutics by 28.0% in the 1st quarter. Ameritas Investment Partners Inc. now owns 5,896 shares of the company’s stock valued at $167,000 after buying an additional 1,291 shares in the last quarter. Public Employees Retirement Association of Colorado acquired a new stake in Dyne Therapeutics during the 2nd quarter valued at $203,000. Finally, Farallon Capital Management LLC purchased a new position in Dyne Therapeutics during the second quarter worth $212,000. Institutional investors and hedge funds own 96.68% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have commented on DYN. StockNews.com downgraded shares of Dyne Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday. Piper Sandler increased their price target on shares of Dyne Therapeutics from $43.00 to $53.00 and gave the stock an “overweight” rating in a report on Tuesday, August 13th. Morgan Stanley lifted their price objective on Dyne Therapeutics from $48.00 to $52.00 and gave the company an “overweight” rating in a report on Wednesday, August 14th. HC Wainwright reissued a “buy” rating and set a $55.00 target price on shares of Dyne Therapeutics in a research note on Wednesday, September 4th. Finally, Oppenheimer reissued an “outperform” rating and issued a $55.00 price target on shares of Dyne Therapeutics in a report on Tuesday, September 3rd. One analyst has rated the stock with a sell rating, nine have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Dyne Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $51.40.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.